• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Advocacy Group Pushes FDA to Disqualify Minneapolis IRB, Investigators from Running Trials

Advocacy Group Pushes FDA to Disqualify Minneapolis IRB, Investigators from Running Trials

November 22, 2021

Public Citizen has called on the FDA to take strong action against two Minneapolis, Minn., investigators and the IRB at Hennepin County Medical Center (HCMC) over IND and informed consent issues on some of their trials.

The two clinical investigators — Jon Cole and Lauren Klein — received warning letters earlier this year for initiating and conducting trials without submitting and obtaining INDs. Though the investigators contended that they didn’t need to seek INDs for their trials because the drugs administered weren’t research interventions, the agency didn’t agree.

In the case of the IRB, it received a Form 483 from an Aug. 7-23, 2018, inspection that identified multiple observations. Among those, the agency observed that the IRB should not have approved waivers of consent for the investigators’ studies. The agency also observed that the IRB had approved research “in a situation where some or all of the subjects were likely to be vulnerable to coercion or undue influence” but didn’t check to see if safeguards had been established to protect these vulnerable patients (who had an impaired ability to give informed consent).

Public Citizen wants the FDA to make an example out of the investigators, their co-investigators and the medical center, arguing that the violations are serious enough that a “slap-on-the-wrist approach for such noncompliance … will not suffice.”

Although CenterWatch Weekly asked the FDA to elaborate on the situation, the agency declined, stating that it would “review the petition and respond directly to the petitioner.”

Hennepin Healthcare issued a statement on Nov. 16, explaining that the FDA had deemed its corrective actions sufficient. The statement also includes a summary of the changes the institute made to bolster its research program.

“Hennepin Healthcare, the Hennepin Healthcare Research Institute and the researchers involved in studies approved in 2014 and 2016 have taken many actions to strengthen and improve the clinical research program across the institution since the studies were closed in 2018,” HCMC said. “These changes have been shared with the FDA in detail and in October the FDA informed the researchers that the measures taken result in compliance with FDA regulations.”

Read the Public Citizen letter here: https://bit.ly/3qK7OKm.

 

To view more CenterWatch Weekly stories, click here.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing